Radiant Bio Closes $35 Million Series A Financing

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver transformative therapies for patients facing life-changing disease, recently announced it has closed a $35 million Series A financing. Radiant has built a best-in-class, proprietary, multi-valent, multi-specific antibody platform called Multabody™. The funds will enable Radiant to further develop the company’s lead clinical candidate, 4-1BB, and move it towards clinical trials.

Arsheen Kaur
Previous

Rehabtronics to Join PressureSmart Consortium for Advancing Pressure Injury Prevention Using AI
Next

Study Demonstrates Reveal 35C’s Impact in the ICU